{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_mixture_components_substance_refPname in Mixture Component Name (approximate match)
Status:
US Approved Rx
(2002)
Source:
BLA021484
(2002)
Source URL:
First approved in 1986
Source:
METRODIN by SERONO
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2003)
Source:
NDA021417
(2003)
Source URL:
First approved in 1942
Source:
NDA004782
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT02579876: Phase 2 Interventional Completed Eosinophilic Esophagitis
(2015)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT04373031: Phase 2 Interventional Active, not recruiting Breast Cancer
(2020)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT03486990: Phase 2 Human clinical trial Completed N/A
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT04670432: Phase 3 Interventional Active, not recruiting Deep Vein Thrombosis
(2020)
Source URL:
Class:
MIXTURE
Class:
MIXTURE
Class:
MIXTURE
Allylprodine (Ro 2-7113) is an opioid analgesic. It is stereoselective, with one isomer being much more active. Allylprodine is included in Schedule I of the US Controlled Substances Act 1970 as a Narcotic with ACSCN 9602 and a 2014 annual aggregate manufacturing quota of 2 grammes.
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE